In today’s world, the integration of biotechnology, medicine and information technology is actively being developed. The main trends in the development of innovative drugs go hand in hand with the development of diagnostic systems, designed to personalize medicine. Complex technical systems and equipment are used in the development and production of drugs. Thus, the current industry of innovative drug development and production has become the locomotive for development of innovation in high-tech countries.
On May 15th 2012 at MIPT, the BioBusiness Incubator was inaugurated, which will continue the formation of the biopharm cluster "Northern" (BPC "Northern") in Dolgoprudny Moscow region, created in the framework of the Federal Target Program, "Development of the Pharmaceutical and Medical Industry of the Russian Federation until 2020 and Beyond". The concept of creating a cluster is supported by the Government of Moscow Region, the Ministry of Industry, Ministry of Health and the Ministry of Education and Science of Russia.
The opening ceremony was attended by the Rector of the Institute, Nikolai Kudryavtsev, the Director of the Department of Chemical Engineering and Bioengineering Technology of the Ministry of Industry and Trade of Russia, Sergey Tsyb, Nobel Laureate in Chemistry, Professor Barry Sharpless, Scripps Research Institute Professor Valery Fokin, member of the Supervisory Board of MIPT, A. Povalko and the CEO of BPC "Northern", Oleg Korzinov. The main immediate objective of the business-incubator is the testing of models on the interaction of private companies with the university. This will "break in" ideas for future projects, which will then "relocate" to a new building. An agreement has already been signed on the opening of eight laboratories and registration of the first five innovative companies.
The first laboratory of the BioBusiness Incubator, a translational research laboratory, organized by the "Chemical Diversity Research Institute", will be chaired by Nobel Laureate Professor Barry Sharpless (Scripps Research Institute, California, USA). The professor believes that biotechnology and medicine will develop very rapidly in the coming decades and that it is advisable for the young to work in this field, and in the Phystech BioBusiness Incubator students will have such an opportunity during upper-level study.
The new BioBusiness Incubator is a structural unit at MIPT, established for developing corporate and faculty laboratories, as well as innovative small businesses, primarily in the area of "living systems". It will be a launching pad for young, innovative entrepreneurs and their ambitious projects. Currently, the incubator is located in one of the buildings of MIPT, occupying an area of over 900 square meters, of which 400 square meters are reserved for laboratories, where the plans of young scientists will be created and implemented.
The strategic plan is that in 2014 the BioBusiness Incubator, with its current and future labs and start-ups, will move into a new biopharmaceutical housing being built at MIPT. During these two years the details and methodology of cooperation and integration of the practice of science and industry will be worked out. In the first year of the formation of the Incubator, it became apparent that the cluster approach can be effectively implemented in practice and contribute not only to "growing" small innovative companies, but also to the creation of corporate R & D departments and funds, as needed to modernize the pharmaceutical and medical industry of Russia.
The BioBusiness Incubator has created more than 100 jobs, which will be distributed between about ten different companies and projects. It is expected that 70–80% of the companies will be connected specifically with pharmaceuticals and medical equipment for development in the area of "living systems", including the pharmaceutical industry, one of the main objectives of the strategic development of MIPT. The remaining 20–30% of the companies will be high-tech projects, launched by MIPT graduates or students in related fields.